Waqar Khalid Saeed

Waqar Khalid Saeed

Auto-generated profile, based on publicly available information

Waqar Khalid Saeed

Department of Internal Medicine, Hanyang University School of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2013 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
SSSung Gon Shim
Sung Gon Shim
DJDae Won Jun
Dae Won Jun
EKEun Kyung Kim
Eun Kyung Kim
WSWaqar Khalid Saeed
Waqar Khalid Saeed
KLKang Nyeong Lee
Kang Nyeong Lee
BYByung Chul Yoon
Byung Chul Yoon

1 December 2014 in European Journal of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
DKDong Shin Kwak
Dong Shin Kwak
DJDae Won Jun
Dae Won Jun
JSJae Gu Seo
Jae Gu Seo
WCWon Seok Chung
Won Seok Chung
SPSoon-Eung Park
Soon-Eung Park
HCHo Soon Choi
Ho Soon Choi
: Although numerous animal studies suggest that probiotic therapy has beneficial effects in various liver diseases, the evidence for beneficial effects in human liver disease is controversial. This study was carried out to investigate the efficacy of probiotic therapy in alleviating small intestinal bacterial overgrowth (SIBO) and permeability in chronic liver disease. Fifty-three patients with chronic liver disease were randomized to either probiotic therapy or placebo. Six bacterial species were used: Bifidobacterium bifidum, Bifidobacterium lactis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus rhamnosus, and Streptococcus thermophilus. After 4 weeks, changes in the composition of fecal bacteria, SIBO, intestinal permeability, and clinical symptoms were examined. Three of the six probiotic species, B. lactis, L. rhamnosus, and L. acidophilus, increased in the feces of the probiotic therapy group (P<0.001), whereas there was no change in fecal microbiota in the placebo group. SIBO disappeared in many individuals of the probiotic therapy group, but none in the placebo (24 vs. 0%, P<0.05). General gastrointestinal symptoms also improved more in the probiotic group and improvement in intestinal permeability was slightly but not significantly more frequent in the probiotic arm than the placebo arm (50 vs. 31.3%, P=0.248). Numbers of lactobacilli in stool were correlated negatively with intestinal permeability (P for trend<0.05). Liver chemistry did not improve significantly in either group. We conclude that short-term probiotic administration in chronic liver disease is effective in alleviating SIBO and clinical symptoms, but ineffective in improving intestinal permeability and liver function.

25 September 2016 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
HOHyunwoo Oh
Hyunwoo Oh
DJDae Won Jun
Dae Won Jun
WSWaqar K Saeed
Waqar K Saeed
MNMindie H Nguyen
Mindie H Nguyen
The prevalence of non-alcoholic fatty liver disease (NAFLD) is estimated to be 25-30% of the population, and is the most common cause of elevated liver enzymes in Korea. NAFLD is a "hot potato" for pharmaceutical companies. Many clinical trials are underway to develop a first-in-class drug to treat NAFLD. However, there are several challenging issues regarding the diagnosis of NAFLD. Currently, liver biopsy is the gold standard method for the diagnosis of NAFLD and steatohepatitis. Ideally, globally recognized standards for histological diagnosis and methods to optimize observer agreement on biopsy interpretation should be developed. Liver biopsy is the best method rather than a perfect one. Recently, multi-parametric magnetic resonance imagery can estimate the amount of intrahepatic fat successfully and is widely used in clinical trials. But no diagnostic method can discriminate between steatohepatitis and simple steatosis. The other unresolved issue in regard to NAFLD is the absence of satisfactory treatment options. Vitamin E and obeticholic acid have shown protective effects in randomized controlled trials, but this drug has not been approved for use in Korea. This study will provide a description of diagnostic methods and treatments that are currently recommended for NAFLD.

1 January 2015 in The Scientific World Journal
Verified
Journal Article
Open access
PDF file
JLJai Sun Lee
Jai Sun Lee
DJDae Won Jun
Dae Won Jun
EKEun Kyung Kim
Eun Kyung Kim
HJHye Joon Jeon
Hye Joon Jeon
HNHo Hyun Nam
Ho Hyun Nam
WSWaqar Khalid Saeed
Waqar Khalid Saeed
Background. We used high‐fat (HF), high‐fructose (HFr), and combination diets to create a dietary animal model of nonalcoholic fatty liver disease (NAFLD). Comparison of both clinical phenotypes has not been well defined. The purpose of this study was to compare histologic and metabolic characteristics between diets in an animal model of NAFLD. Methods. NAFLD was induced in rats by feeding them HF, HFr, and combination (HF + HFr) diets for 20 weeks. The degree of intrahepatic fat accumulation, inflammation, and oxidative stress was evaluated. Metabolic derangements were assessed by the oral glucose tolerance test and the intrahepatic insulin signal pathway. Results. Body weight gain and intrahepatic fat accumulation were more prominent in the HF feeding group than in the HFr group. The expressions of NOX‐4 and TLR‐4 were higher in the HF and HFr combination groups than in the HF‐only group. Other intrahepatic inflammatory markers, MCP‐1, TNF‐α, and endoplasmic reticulum stress markers, were the highest in the HF + HFr combination group. Although intrahepatic fat deposition was less prominent in the HFr diet model, intrahepatic inflammation was noted. Conclusions. Intrahepatic inflammation and metabolic derangements were more prominent in the HF and HFr combination model than in the HF monodiet model.

27 May 2019 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
WSWaqar Khalid Saeed
Waqar Khalid Saeed
DJDae Won Jun
Dae Won Jun
KJKiseok Jang
Kiseok Jang
JOJu Hee Oh
Ju Hee Oh
YCYeon Ji Chae
Yeon Ji Chae
HKHyeon Tae Kang
Hyeon Tae Kang

1 October 2019 in Pharmacological Research
Verified
Journal Article
Closed access
WSWaqar Khalid Saeed
Waqar Khalid Saeed
DJDae Won Jun
Dae Won Jun
KJKiseok Jang
Kiseok Jang
DKDong Hee Koh
Dong Hee Koh